ryr3 (Alomone Labs)
Alomone Labs is a verified supplier 
Alomone Labs manufactures this product 
92
Structured Review
Alomone Labs
ryr3
Ryr3, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 92/100, based on 8 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ryr3/Anti-Ryanodine+Receptor+3+Antibody/bio_rxiv__64898__2025__12__28__696549-278-54-55
Average 92 stars, based on 8 article reviews
Ryr3, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 92/100, based on 8 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ryr3/Anti-Ryanodine+Receptor+3+Antibody/bio_rxiv__64898__2025__12__28__696549-278-54-55
Average 92 stars, based on 8 article reviews
ryr3 - by Bioz Stars,
2026-09
92/100 stars
Images
1) Product Images from "FAM84B facilitates tau propagation via RYR3-mediated exocytosis in response to neuroinflammation"
Article Title: FAM84B facilitates tau propagation via RYR3-mediated exocytosis in response to neuroinflammation
Journal: bioRxiv
doi: 10.64898/2025.12.28.696549
Figure Legend Snippet: (A) Differentially expressed genes in HEK293 cells in response to FAM84B KO (n=3 each). Genes with p < 0.05 and >2-fold expression change compared to control are marked with red dots. (B) Differentially expressed genes in HEK293 cells in response to FAM84B OE (n=3 each). Genes with p < 0.05 and >2-fold expression change compared to control are marked with red dots. (C) Differentially expressed genes in tau-expressing SH-SY5Y cells in response to FAM84B OE (n=3 each). Genes with p < 0.05 and >1.7-fold expression change compared to cells expressing tau alone are marked with red dots. (D) Venn diagram showing the number of shared genes between RNA-seq datasets in (A–C), with overlapping genes represented in distinct colors (red, green, black, blue). Only the names of membrane-related genes among the shared genes are noted. (E) GO analysis showing cellular compartments of genes identified in (D). The GO terms based on the number of genes are shown. (F) Levels of RYR3 and actin in iPSC-derived CN from HC and patients with AD (n=3 each). (G) Levels of RYR3 and actin in SH-SY5Y cells expressing tau alone or tau with FAM84B-Myc (n=3 each). (H) Colocalization (arrow) of FAM84B and calcium in SH-SY5Y cells expressing tau with mCherry control (C1), and in cells expressing tau with mCherry-FAM84B treated with either DMSO or dantrolene (n=4 each). (I) PHF-1 spread from SH-SY5Y cells expressing Tau-p2a-eGFP with FAM84B to neighboring cells in response to treatment with either DMSO or dantrolene (n=4 each). Arrows indicate recipient cells (red) to which tau has been transmitted. Solid boxes in the images indicate magnified areas. Results are presented as mean ± SEM. Co-localization analysis. (H) Pearson correlation coefficient. Statistical analyses: (A-C, F-I) unpaired two-tailed t -test with Welch’s correction; ns: not significant, *p < 0.05, **p < 0.01, ***p < 0.001. Abbreviations: KO, knockout; OE, overexpression; GO, gene ontology; CN, cortical neuron; HC, healthy control; AD, Alzheimer’s disease; PHF-1, phosphorylated tau at residues S396/S404; FOV, field of view.
Techniques Used: Expressing, Control, RNA Sequencing, Membrane, Derivative Assay, Two Tailed Test, Knock-Out, Over Expression
Figure Legend Snippet: (A) Venn diagram showing the seven shared transcriptional cofactors between the ENCODE ChIP-seq and CHEA ChIP-seq datasets. The genes are categorized into functional terms and noted. (B) Genomic information of the FAM84B gene obtained from the UCSC Genome Browser. Transcription cofactor clusters identified from the ENCODE ChIP-seq data, with those likely to bind to the regulatory elements of FAM84B, as identified by FANTOM5, highlighted. (C) Levels of phosphorylated STAT3 (Y705) in the cerebral cortex of HC (n=3) and patients with VD (n=3), CBD (n=3), PSP (n=4), PART (n=3), and AD (n=6). (D) Levels of phosphorylated STAT3 (Y705) and total STAT3 in iPSC-derived CN from HC and patients with AD (n=3 each). (E) Levels of phosphorylated STAT3 (Y705), total STAT3, FAM84B, and actin in SH-SY5Y cells treated with either control vehicle or IL-6 (n=3 each). (F) Changes in the levels of phosphorylated STAT3 (Y705), total STAT3, FAM84B, and actin in SH-SY5Y cells expressing STAT3-WT or STAT3-DN in response to treatment with either control vehicle or IL-6 (n=3 each). (G) PHF-1 spread from Tau-p2a-eGFP expressing SH-SY5Y cells to neighboring cells in response to treatment with either control vector or IL-6 (n=4 each). Arrows indicate recipient cells (red) to which tau has been transmitted. Solid boxes in the images indicate magnified areas. (H) PHF-1 spread from IL-6 treated SH-SY5Y cells expressing Tau-p2a-eGFP to neighboring cells in response to treatment with either DMSO or dantrolene (n=4 each). Arrows indicate recipient cells (red) to which tau has been transmitted. Solid boxes in the images indicate magnified areas. (I) Changes in the levels of PHF-1, total tau, phosphorylated STAT3 (Y705), total STAT3, FAM84B (FAM84B-Myc), RYR3, and actin in iPSC-derived CN from HC after infection with AAV and subsequent treatments (n=3 each). (J) Changes in the levels of phosphorylated tau (T181 and S396) in the CM of iPSC-derived CN from HC after infection with AAV and subsequent treatments (n=8 each). In (I–J), the experimental groups are: (1) CN infected with AAV containing tau, (2) CN infected with AAV containing tau and FAM84B-Myc, (3) CN infected with AAV containing tau and treated with IL-6 and TNF-α, (4) CN infected with AAV containing tau and FAM84B-Myc and treated with dantrolene, and (5) CN infected with AAV containing tau, treated with IL-6 and TNF-α, followed by treatment with dantrolene. Results are presented as mean ± SEM. Statistical analyses: (C) ordinary two-way ANOVA; (D-J) unpaired two-tailed t -test with Welch’s correction; ns: not significant, *p < 0.05, **p < 0.01, and ***p < 0.001. Abbreviations: HC, healthy control; VD, vascular dementia; CBD, corticobasal degeneration; PSP, progressive supranuclear palsy; PART, primary age-related tauopathy; AD, Alzheimer’s disease; CN, cortical neuron; WT, wild type; DN, dominant negative; PHF-1, phosphorylated tau at S396/S404 residue; FOV, field of view; AAV, adeno-associated virus; CM, conditioned media.
Techniques Used: ChIP-sequencing, Functional Assay, Derivative Assay, Control, Expressing, Plasmid Preparation, Infection, Two Tailed Test, Dominant Negative Mutation, Residue, Virus
Related Articles
Transferring:Article Title: Reduced DHPRα1S and RyR1 expression levels are associated with diaphragm contractile dysfunction during sepsis. Article Snippet: Introduction: Sepsis often causes diaphragm contractile dysfunction.. Dihydropyridine receptors (DHPRa1s and DHPRa1c) and ryanodine receptors (RyR1, RyR2, and RyR3) are essential for excitation–contraction coupling in striated muscles.. However, their expression in diaphragm during sepsis have not been explored. Membrane:Article Title: Reduced DHPRα1S and RyR1 expression levels are associated with diaphragm contractile dysfunction during sepsis. Article Snippet: Introduction: Sepsis often causes diaphragm contractile dysfunction.. Dihydropyridine receptors (DHPRa1s and DHPRa1c) and ryanodine receptors (RyR1, RyR2, and RyR3) are essential for excitation–contraction coupling in striated muscles.. However, their expression in diaphragm during sepsis have not been explored. Incubation:Article Title: Reduced DHPRα1S and RyR1 expression levels are associated with diaphragm contractile dysfunction during sepsis. Article Snippet: Introduction: Sepsis often causes diaphragm contractile dysfunction.. Dihydropyridine receptors (DHPRa1s and DHPRa1c) and ryanodine receptors (RyR1, RyR2, and RyR3) are essential for excitation–contraction coupling in striated muscles.. However, their expression in diaphragm during sepsis have not been explored. Article Title: Aging alters spontaneous and neurotransmitter-mediated Ca 2+ signaling in smooth muscle cells of mouse mesenteric arteries Article Snippet: Smooth muscle cells adhered to slides were fixed in 4% paraformaldehyde for 15 min, gently washed twice in phosphate-buffered saline (PBS; Cat. #P5368; Sigma), blocked with 10% normal goat serum and permeabilized for 30 min in PBS containing 10% normal goat serum and 0.1% Triton X100, then washed with PBS alone. .. Thus prepared, slides were incubated 60 min in primary antibody [Alamone Labs, 1:250] for RyR1 (Cat. #ARR-001), RyR2 (Cat. #ARR-002), or Article Title: FAM84B facilitates tau propagation via RYR3-mediated exocytosis in response to neuroinflammation Article Snippet: The membranes were blocked in a solution containing 5% bovine serum albumin (GenDEPOT) and skim milk (Cell Signaling Technology, Danvers, MA, USA) for one hour at room temperature to enhance the detection of the phosphorylated and native forms of the proteins. .. Following blocking, membranes were incubated overnight at 4°C with primary antibodies (1:1,000 dilution), including: PHF-1 (Peter Davies Lab), Tau5 (Gail VW Johnson Lab), Tau (Dako, Agilent Technologies, Inc., 0024), Myc-tag (Cell Signaling Technology, 2276), FAM84B (OriGene, TA501992; Proteintech Group, Inc., Rosemont, IL, USA, 18421-1-AP), Alix (Cell Signaling Technology, 2171), Caveolin-1 (Cell Signaling Technology, 3267), Blocking Assay:Article Title: FAM84B facilitates tau propagation via RYR3-mediated exocytosis in response to neuroinflammation Article Snippet: The membranes were blocked in a solution containing 5% bovine serum albumin (GenDEPOT) and skim milk (Cell Signaling Technology, Danvers, MA, USA) for one hour at room temperature to enhance the detection of the phosphorylated and native forms of the proteins. .. Following blocking, membranes were incubated overnight at 4°C with primary antibodies (1:1,000 dilution), including: PHF-1 (Peter Davies Lab), Tau5 (Gail VW Johnson Lab), Tau (Dako, Agilent Technologies, Inc., 0024), Myc-tag (Cell Signaling Technology, 2276), FAM84B (OriGene, TA501992; Proteintech Group, Inc., Rosemont, IL, USA, 18421-1-AP), Alix (Cell Signaling Technology, 2171), Caveolin-1 (Cell Signaling Technology, 3267), other:Article Title: Lysosomal calcium is modulated by STIM1/TRPML1 interaction which participates to neuronal survival during ischemic preconditioning Article Snippet: © 2021 Federation of American Societies for Experimental Biology Abbreviations: CaMKKβ, calcium/calmodulin-dependent protein kinase kinase β; ER, endoplasmic reticulum; GPN, Gly-Phe β-naphthylamide; IPC, ischemic preconditioning; IP3R, inositol 1,4,5-triphosphate receptor; LAMP1/2, lysosomal-associated membrane protein 1/2; ML-SA1, 2-(2-Oxo-2-(2,2,4trimethyl-3,4-dihydroquinolin-1(2H)-yl)ethyl)isoindoline-1,3-dione; OGD/Rx, oxygen and glucose deprivation followed by reoxygenation; PI(3,5)P2 diC8, phosphatidylinositol 3,5-bisphosphate diC8; RyR, ryanodine receptor; ROS, reactive oxygen species; SERCA, sarco-endoplasmic reticulum calcium ATPase; SOCE, store-operated Ca2+ entry; STIM1, stromal interacting molecule 1; TFEB, transcription factor EB; TRPC1, transient receptor potential canonical 1; TRPML1, transient receptor potential mucolipin channel 1.. 1Division of Pharmacology, Department of Neuroscience, Reproductive and Odontostomatological Sciences, School of Medicine, “Federico II” University of Naples, Naples, Italy 2Division of Pharmacology, Department of Science and Technology-DST, University of Sannio, Benevento, Italy |
![Effect of blocking L-type calcium channels with nifedipine and <t>ryanodine</t> <t>receptors</t> with dantrolene on ATP and BzATP-induced peak [Ca 2+ ] i . Cultured rat conjunctival goblet cells were preincubated with nifedipine (Nif) (10 −5 M) for 15 min and/or dantrolene (Da) (10 −5 M) for 30 min before stimulation with ATP (10 −5 M) ( A ) or BzATP (10 −4 M) ( B ). A and B : the average [Ca 2+ ] i over time. Arrows represent the addition of agonists. C : the peak increase of [Ca 2+ ] i above baseline. ATP: bars to the left of the central vertical dotted line in C , BzATP: bars to the right of the central vertical dotted line in C . Data are presented as means ± SE. n = 3. BzATP, benzoylbenzoyl-ATP; [Ca 2+ ] i , intracellular calcium concentration. *Statistically significant difference from agonist alone.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_7011/pmc11427011/pmc11427011__ajpcell.00291.2024_f007.jpg)
![Proposed regulation of intracellular calcium levels by ryanodine receptor 3 (RyR3) in cultured rat conjunctival goblet cells. ATP and BzATP may increase [Ca 2+ ] i : 1 ) directly by activating RyR3, 2 ) by activating purinergic 1 (P1) receptors after the enzymatic conversion to metabolites, 3 ) by the activation of purinergic 2 (P2) receptors directly, and 4 ) by activating L-type calcium channels through membrane depolarization. These mechanisms can then either directly increase [Ca 2+ ] i through the influx of extracellular Ca 2+ and/or through the activation of RyR3 on an intracellular compartment such as the ER to release Ca 2+ . BzATP, benzoylbenzoyl-ATP; [Ca 2+ ] i , intracellular calcium concentration; CGCs, conjunctival goblet cells; CICR, calcium-induced calcium release.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_7011/pmc11427011/pmc11427011__ajpcell.00291.2024_f013.jpg)